がん領域における共同研究およびライセンシング契約：2019年～2024年

当レポートでは、がん領域の共同研究およびライセンシング案件について調査し、2019年以降の契約動向、がん領域の共同研究およびライセンシング案件、ベンチマーク分析- 取引の市場価値、財務条件、主な取引額、最も活発なディールメーカーなどについてまとめています。

目次

エグゼクティブサマリー

第1章 -イントロダクション

第2章 がん領域取引の動向

• イントロダクション
• がん領域での長年の提携動向
• がん領域の提携、取引タイプ別
• がん領域の提携、産業分野別
• がん領域の提携、開発段階別
• がん領域の提携、技術タイプ別
• がん領域の提携、治療適応症別

第3章 -がん領域提携に関する金融取引条件

• イントロダクション
• がん領域の提携に関する公開された財務条件
• がん領域の提携のヘッドライン値
• がん領域の取引の前払い
• がん領域の取引のマイルストーンペイメント
• がん領域の取引のロイヤルティ率

第4章 -主要ながん領域取引と取引担当者

• イントロダクション
• がん領域との提携が最も活発
• がん領域で最も活発なディールメーカーのリスト
• がん領域の取引額上位

第5章 -がん領域契約文書ディレクトリ

• イントロダクション
• 契約書が入手可能ながん領域提携取引

第6章 治療ターゲット別がん領域の取引

• イントロダクション
• がん領域治療標的別の取引
• 取引ディレクトリ
• 取引ディレクトリ- がん領域取引、企業別（2019年～2024年）
• 取引ディレクトリ- がん領域取引、技術タイプ別（2019年～2024年）
• 取引タイプの定義
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 3,850 oncology deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

• Trends in oncology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of oncology deal records covering pharmaceutical and biotechnology
• The leading oncology deals by value
• Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z 2019 to 2024
• Deal directory - Oncology deals by technology type 2019 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2019
• Figure 2: Oncology partnering by deal type since 2019
• Figure 3: Oncology partnering by industry sector since 2019
• Figure 4: Oncology partnering by stage of development since 2019
• Figure 5: Oncology partnering by technology type since 2019
• Figure 6: Oncology partnering by indication since 2019
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2019
• Figure 12: Top oncology deals by value since 2019